Credit: Novartis. The approval was based on data from the ORION-9, ORION-10, and ORION-11 trials that evaluated Leqvio in patients 18 years of age and older with HeFH or clinical ASCVD. The Food and ...

Sometimes diet and exercise are not enough to lower cholesterol levels. Many different medicine options exist, including Leqvio, which can be used alone or with other medicines to help people reach ...

Patients with statin resistance do not experience symptoms, Le noted. Instead, the problem is that statins do not lower LDL-C levels as much as they typically do. Instead of a 50% reduction, people ...

Wednesday, Novartis AG (NYSE:NVS) released topline results from twice-yearly Leqvio (inclisiran) in the Phase 3 V-MONO study, which met its primary endpoints. V-MONO is part of the 60,000-patient ...

The drug, inclisiran, is part of a relatively new class of genetic medicines that work by stopping production of a problem protein. In the case of the Novartis drug, which will be marketed under the ...

Novartis NVS announced positive data on the cholesterol drug Leqvio (inclisiran) from the late-stage V-MONO study. Leqvio is the first and only small interfering RNA (siRNA) therapy to lower ...

FRISCO, Texas--(BUSINESS WIRE)--Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has been selected as a limited distribution partner ...

Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package insert ...

After an initial dose and one at 3 months, inclisiran (Leqvio) is administered twice per year as a subcutaneous injection, according to a press release issued by the company. Source: Adobe Stock The ...